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Abstract 
 
 Stress has been proposed to be a tumor promoting factor through the secretion of 
specific neuromediators, such as Urocortin2 and 3 (Ucn2/3), however its role in colorectal 
cancer (CRC) remain elusive. We observed that Ucn2/3 and their receptor the Corticotropin 
Releasing Factor receptor 2 (CRF2) were up-regulated in high grade and poorly differentiated 
CRC. This suggests a role for CRF2 in the loss of cellular organization and tumor 
progression. Using HT-29 and SW620 cells, two CRC cell lines differing in their abilities to 
perform cell-cell contacts, we found that CRF2 signals through Src/ERK pathway to induce 
the alteration of cell-cell junctions and the shuttle of p120ctn and Kaiso in the nucleus. In HT-
29 cells, this signaling pathway also leads to the remodeling of cell adhesion by i) the 
phosphorylation of Focal Adhesion Kinase and ii) a modification of actin cytoskeleton and 
focal adhesion complexes. These events stimulate cell migration and invasion. In conclusion, 
our findings indicate that CRF2 signaling controls cellular organization and may promote 
metastatic potential of human CRC cells through an epithelial-mesenchymal transition like 
process. This contributes to the comprehension of the tumor-promoting effects of stress 
molecules and designates Ucn2/3-CRF2 tandem as a target to prevent CRC progression and 
aggressiveness. 
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Introduction 
 Colorectal cancer (CRC) is the second leading cause of cancer-related death in 
Western countries. Histological grade is an important prognostic marker as high-grade, poorly 
differentiated tumors are usually more aggressive and invasive than their low-grade, well-
differentiated counterparts. A hallmark of CRC is loss of cellular organization. Adhesive 
interactions between cells and extracellular matrix (ECM) are key determinants of tissue 
organization and their modulations participate in cell migration and tumor metastasis.  
In epithelial cells, cell-cell adhesion is maintained through several protein complexes 
such as adherens junctions (AJ). Cadherins are transmembrane proteins that nucleate AJ by 
forming homotypic calcium dependent interactions with cadherins from neighboring cells. 
Manipulation of E-cadherin function in the intestinal epithelium has revealed an important 
role in cell differentiation or cell/matrix adhesion [1]. E-cadherin is diminished in invasive 
CRC together with the acquisition of a mesenchymal phenotype [2]. The intracellular domain 
of E-cadherin interacts directly with β- and p120 catenins (ctn). They regulate AJ by 
controlling cadherin clustering, endocytosis or stability and actin cytoskeleton anchorage 
(reviewed in [3]). In E-cadherin deficient cells p120ctn shuttles to the cytoplasm and/or the 
nucleus where it exerts different functions depending on its partners [4,5]. In the nucleus, 
p120ctn can interact with the transcription factor Kaiso and relieves its gene repression 
activity [6,7]. Abnormal nuclear localization of p120ctn and Kaiso is prognostic for 
aggressiveness in CRC [8].  
 Micro-environment controls cancer progression through cell contacts or mediator 
signals [9]. The corticotropin releasing factor (CRF) and analogs like urocortins (Ucns) [10] 
are secreted peptides related to stress. They act through two G protein coupled receptors 
(GPCR), CRF1 and CRF2, with different affinities [11]. CRF and Ucn1 bind both receptors, 
while Ucn2/3 are selective for CRF2. CRF receptors are primarily coupled to Gαs and trigger 
cAMP formation via adenylyl cyclase activation [12]. If CRF system is well documented in 
the gastrointestinal tract for its expression and regulation by stress and inflammation, its 
implication in CRC is poorly investigated [13,14]. Ligands and receptors are expressed and 
secreted by various normal and cancer cells. Therefore, CRF system could modulate the 
tumor micro-environment by autocrine/paracrine activations on cancer or stromal cells 
[9,15,16]. The aim of this study was to determine the expression of CRF2 and its ligands in 
CRC and how their signaling could participate in the tumor progression. Our results described 
aberrant expression of CRF2 and ligands in both CRC tumors and cell lines, according to their 
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grade and/or differentiation status. Using the HT-29 and SW620 cell lines, we discovered that 
CRF2 signaling modifies cellular adhesion and established a mechanism by which stress 
molecules may participate in tumor progression. 
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Materials and Methods 
 
Cell culture 
 The human colon adenocarcinoma cell lines HT-29 and SW620 obtained from the 
American Type Culture Collection (ATCC, Manassas, VA) were cultured at 37°C in a 5% 
CO2 atmosphere in DMEM containing 25 mM glucose (Invitrogen, Cergy Pontoise, France) 
and supplemented with 10% FCS, 5% penicillin and streptomycin. The human CRF2-GFP 
construct was cloned into the pBabe expression vector. Retroviral infections of HT-29 cells 
were done as described previously [17] and then cultured in medium containing 2µg/ml 
puromycin (BD Biosciences), following to FACS selection of virus-infected cells. 
 
Antibodies and reagent 
 Polyclonal antibodies directed against CRF2 were from Abcam (12964, Paris, France). 
The immunizing peptide used to generate the CRF2 antibody was designed in the conserved 
sequence of the α, β and γ isoforms. This antibody would then recognize all isoforms of the 
receptor. Anti-human E-cadherin (HECD1) monoclonal antibody was obtained from Takara 
Biochemicals (Cambrex Bio Science, Paris, France). Monoclonal antibody against p120ctn 
(clone 98) was purchased from BD Transduction Laboratories (Pont de Claix, France). Anti-
actin, anti-MMP3 polyclonal antibodies, and anti-Kaiso,  anti-vinculin monoclonal antibodies 
were obtained from Sigma Aldrich (L'Isle d'Abeau, France). Polyclonal antibodies directed 
against Src-PTyr418 were purchased from MBL Calbiochem (Fontenay-sous-Bois, France), 
monoclonal anti-Src and anti-MMP7 antibodies were from Millipore (Molsheim, France). 
Monoclonal antibodies against ERK and ERK-PTyr204 were from BD transduction laboratories 
and Santa cruz from TEBU (Le perray en Yvelines, France) respectively. Polyclonal anti-
FAK-PSer910 antobodies were obtained from Invitrogen (Cergy Pontoise, France). Alexa–
conjugated goat anti-mouse secondary antibody was obtained from Molecular Probes 
(Eugene, OR). Horse Radish Peroxydase–conjugated goat anti-mouse secondary antibody was 
obtained from Bio-Rad (Marnes-la-Coquette, France), donkey anti-rabbit antibodies were 
obtained from Jackson Immunoresearch (Immunotech, Marseille, France). Topro3 was 
purchased from Invitrogen. Urocortins, CRF and Astressin 2b were purchased from Sigma 
Aldrich.  
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Patient cohort, Tissue Micro Arrays and immunohistochemistry 
 This study was conducted on cDNA of a cohort of 30 CRC patients. Samples from 
frozen tumor and peritumoral tissues were obtained from the Tumor Tissue Bank of Hospices 
Civils de Lyon, supported by National Institute of Cancer (INCa) and French Ministery of 
Health. The tissue bank conforms to French regulations. All patients have given written 
informed consent to the use of tissue samples for research purposes; in the absence of 
informed consent, tissue samples from patients known to be deceased could also be used for 
research purposes, in accordance with French regulations. Procedures for collection, storage 
and release of tissue samples are in accordance with national and international 
recommendations and a quality management programme has been developed. All projects 
submitted to the tissue bank are reviewed and approved by its Scientific Committee, which 
also verifies their conformity to ethical regulations. To preserve anonymity, a specific ID was 
attributed to each patient. For each sample, the cDNA from tumoral tissue was paired with the 
cDNA of the adjacent normal tissue. The tumor stages were defined according to the TNM 
status of the tumors (American Joint Committee on Cancer Staging system). Tissue Micro 
Arrays (TMA) CDA3 were purchased at SUPER BIO CHIPS (Korea). The slide was blocked 
in TBS /BSA 3% /Tween-20 0.1% and incubated over night at 4°C with anti-CRF2 at 1:100. 
The further IHC was performed with Vectastain ABC Kit (Vector Laboratories, Courtaboeuf, 
France), counterstained with 1 min incubation in Hematoxylin, dehydrated and mounted with 
DPX. Every microscope acquisitions were down in “TRIBUN” and quantified with Image J. 
The IHC quantifications were performed in ImageJ WCIF with the CIE Lab function of the 
color based thresholding segmentation to separate the CRF2 staining from the Hematoxylin 
counter-staining. Six different fields of every sample were segmented and the mean gray 
value was calculated for the CRF2 and the Hematoxylin. The CRF2 intensity for each sample 
is the mean of the CRF2/Hematoxylin ratio calculated on the six different fields. 
 
Cell fractionation 
 For nuclear fractionation, cell were lysed in HEPES 10mM /MgCl2 1.5mM /KCl 
10mM / DTT 0.5mM /NP40 0.05% /pH 7.9.  After a 10 min centrifugation at 3000 rpm and 
4°C, pellets were resuspended in HEPES 5mM / MgCl2 1.5mM /EDTA 0.2mM /DTT 0.5mM 
/glycerol 26% (v/v) /pH 7.9, and homogenized with 20 full strokes in Dounce. After 30 min 
incubation on ice, lysates were centrifuged 20 min at 24000 g and 4°C. Supernatants 
containing nuclear extracts were analyzed by immunoblot. 
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Immunoblot and Immunoprecipitation 
 Total lysates or subcellular fractions were processed for immunoblot as described 
previously [18].  
 
Immunofluorescent staining 
 Cells were grown on glass coverslips and then treated as described previously [18]. 
After fixation with PFA 4% sucrose, non-specific sites were blocked for 1 hr at 37°C with 3% 
BSA 0.5% Tween20. Then cells were incubated for 1 hr at 37°C with specific antibodies 
which were diluted in the blocking solution at 1:100 for primary and 1:500 for secondary 
antibodies. Fluorescence photomicrographs were taken with a confocal microscope at the 
x100 objective (Leica TCS SPE) or an epifluorescence microscope at the x100 objective 
(ZEISS, AvioVert 200M).  
 
RT and qPCR 
Total RNA extractions were performed using TrizolTM reagent and 1µg of total RNA 
was denaturized and subsequently processed for reverse transcription using M-MLV 
(Invitrogen) according to manufacturer’s instructions. qRT-PCR were done with a Light 
cycler 480 and the universal probe library (Roche). Primer sequences and probes are 
summarized in supplementary Table 1. 
 
ECM preparation and cell adhesion 
Tissue culture dishes were coated with LM-332 using the following methods: A431 epidermoid 
cells were cultured to confluence on various surfaces at 37°C to allow for the deposit of LM-
332, then cells were removed as previously described [19,20]. Briefly, confluent monolayers 
were sequentially extracted with 1% (v/v) Triton X-100 in PBS, followed by 2M urea in 1M 
NaCl. Plates were washed in PBS, incubated with 1%BSA, and stored at -20°C. Human 
collagen type IV from placenta was obtained from Sigma Aldrich. Coating of plastic Petri 
dishes (Microtiter plates 96-well, Nunclone; Nunc, Roskilde, Denmark) was performed by 
overnight incubation with ECM proteins (10 µg/mL) at 4°C. Plates were saturated with 3% (w/ 
v) BSA in PBS for 2 hrs at 37°C. HT-29 CRF2-GFP cells were pretreated or not with 100 nM 
Ucn3 for 30 min before to be plated (5x104 cells/ well) in triplicate in coated 96-well microtiter 
plates and incubated from 0 to 60 min at 37°C. Non adherent cells were removed by washing 
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three times with PBS, and cell adhesion was estimated by a cell proliferation assay (CellTiter 
96 AQueous Non-Radioactive Cell Proliferation Assay; Promega). 
 
Cell transmigration and invasion 
HT-29 CRF2-GFP cells were seeded on 24 well transwells (8 µM pore size) (Becton 
Dickinson). After cell confluence, the culture medium was serum harvested over night in up 
and down chambers. Transmigration was then initiated by establishment of a serum gradient 
with 10% FCS in the lower chamber, with or without 100 nM Ucn3 in each chamber. 72 hrs 
after the initiation of transmigration, cotton swabs were used to remove cells on the upper 
surface of transwells. After fixation with PFA 4%, migratory cells were stained with 
Hematoxylin and manually counted under the microscope. The mean values +/-SEM were 
calculated and analyzed using Student’s test. 
HT-29 CRF2-GFP cells (2.5 10-5/ mL) were placed in the top compartment of a 24-
multiwell insert insert plate (BD Falcon) that was separated from the bottom compartment by 
BD-Matrigel Matrix membrane, with 0.4-µm pore size. Serum-free RPMI with or without 
Ucn3 (1 µM) were added into the top compartment and 10% FCS into the bottom 
compartment. After 48 hrs at 37°C in a 5% CO2 atmosphere, cells that had invaded through 
the Matrigel, were analyzed as described before for the transmigration assay.  
 Cell viability was evaluated with the CellTiter 96 Kit (Promega) according to the 
manufacturer’s instructions. 
 
Gelatin degradation assay 
  About 40 µL (20-30 µg cell protein) harvested culture medium were electrophoresed 
under nonreducing conditions in a 10% acrylamide gel containing 1 mg/mL gelatine (Sigma-
Aldrich), according to the method described by Werb and al., [21]. After electrophoresis, the 
gels were washed at room temperature for 3 X 30 min in 2% Triton X-100 and overnight at 
37°C in buffer containing 20 MM Tris-HCl (pH 7.7) and 5 mM CaCl2.Thereafter, gels were 
stained with 0.1% (wt/vol) Coomassie Brillant Blue R-250 in 50% (vol/vol) isopropyl 
alcohol/10% (vol/vol) glacial acetic acid for 60 min and destained in 20% (vol/vol) isopropyl 
alcohol/5% (vol/vol) glacial acetic acid. 
 
Densitometric analysis and statistics 
 Immunoblots shown are representative of at least three independent experiments. All 
graphs represent the mean value ± SD of protein expression levels measured by densitometric 
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analysis in “Image J” software (NIH). The relative expression levels of mRNA or proteins 
were determined as follows: the expression of level of each transcript or protein was 
normalized to i) their housekeeping gene in qPCR or RT-PCR; ii) to actin in whole lysate 
westernblots or histones in nuclear extract westernblots. In some experiments and in order to 
display a fold increase over control, the relative expression of transcripts or proteins in control 
conditions was set to 1. Statistics are unpaired t-test and statistical significance is given by the 
number of asterisks (*P<0.05; **P<0.01; ***P<0.001). 
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Results 
Expression of CRF2 and its ligands increase with staging in CRC tissues and cell lines.  
We have first performed qPCR for CRF2α (the major CRF2 isoform of colonic 
epithelium), [22] and Ucn2/3 in normal and CRC tissues of 30 patients, to better understand 
their regulation during tumor progression (Figure 1A). The clinicopathological findings of the 
tumors used in the study are shown in Table 2. Tumors were clustered in low (n=19, 
corresponding to stages 1-2) and high (n=11, corresponding to stages 3-4) grades and 
standardized to their normal tissues. Statistical analysis revealed a significant increase of 
CRF2α and Ucn3 mRNA expression in tumors compared to normal tissues according to the 
tumor grade. There were no significant differences of Ucn2 transcripts in these conditions. 
However, when the analysis was done in tumors tissues only, a pattern was revealed regarding 
Ucn2 mRNA expression: Ucn2 transcript levels were increased according to the pNM status, 
the lymph node invasion and microsatellite instability (MSI). Finally, CRF2α, Ucn2 and 
Ucn3 transcript levels didn’t correlate to mutations of K-ras or B-raf. A similar result was 
found with CRC cell lines (supplemental Figure 1, S1).  Immunohistochemical analysis was 
used in order to detect CRF2 receptor protein expression in colorectal sections corresponding 
to normal tissues (n=9), low grade (n=24) and high-grade (n=18) tumors (Figure 1B). The 
proportion of samples greater than the mean of normal tissues increased from 22% in normal 
to 33% and 72% in low and high-grade tumors respectively (Figure 1C, left panel). Moreover, 
the CRF2 protein expression increased according to the tumor grade (ANOVA p= 0.047) 
(right panel). These results suggest a relationship between CRF2 protein expression and 
higher tumor grades. We extended our analysis by qPCR in 17 human CRC cell lines 
(supplemental Figure 1, S1). Interestingly, we found that the expression of CRF2 ligands is 
inversely correlated to epithelial differentiation markers like E-cadherin (Cdh1) but correlated 
to mesenchymal makers like vimentin (Vim), suggesting a role of CRF2 in the cellular 
disorganization observed during tumor progression. Two CRC cell lines were selected:  i) 
HT-29 cells, which express high level of E-cadherin but low level of Ucn2 and no vimentin; 
ii) SW620 cells, poorly differentiated mesenchymal cells which express high levels of Ucn2 
and vimentin compared to a weak level of E-cadherin (Figure 2A). The expression of CRF2 
and E-cadherin at the protein level was confirmed by immunoblotting (Figure 2B). Using HT-
29 cells that stably overexpress the CRF2 coupled to GFP protein (HT -29 CRF2-GFP cells) 
we observed that CRF2-GFP was predominantly localized at the membrane, in intercellular 
contacts (Figure 2C). This observation was further supported by microscopy confocal analysis 
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showing a co-localization of CRF2-GFP protein with E-cadherin in HT-29 cells (Figure 2D). 
With Ucn3 (the most efficient CRF2 agonist in HT-29 cells, see Figure S2), cells contacts 
were altered and CRF2-GFP shifted in cytoplasmic vesicles (Figure 2C). 
 Altogether, these data indicate that CRF2 and its ligands are expressed in human CRC 
and cell lines according to the tumor grade and/or differentiation status. CRC cells could 
activate their CRF2 via an autocrine production of ligands, especially in undifferentiated cell 
lines. 
 
Regulation of cell-cell contacts by CRF2 signaling   
 CRF2 signalization has been recently extended to non canonical GPCR pathways, 
including Src kinase which directly interacts with the endocytosed CRF receptors and takes 
part in the activation of ERK [23,24]. Src-PTyr418 expression was progressively increased from 
5 to 30 min, while the total Src remained unchanged (Figure 3A). The phosphorylated form of 
Src has been co-immunoprecipitated with CRF2 during the early stage of the kinetic (Figure 
S3A). In CRC, Src kinase activation correlates to E-cadherin disturbance, histological grading 
and poor prognosis [25]. We thus investigated the involvement of Src activity in Ucn3-
mediated cell dissociation. In HT-29 cells, confocal microscopy analysis showed that E-
cadherin staining produced a honeycomb like pattern at the lateral membrane cortex (Figure 
3B). Activation of CRF2 by Ucn3 rapidly altered this pattern. Only a thickened and disrupted 
linear membrane staining persisted while numerous cytoplasmic accumulations appeared, 
indicating an endocytosis of E-cadherin associated to AJ disruption. Cycloheximide was used 
to prevent the accumulation of neosynthesized E-cadherin. Internalization assays using 
HECD-1 antibodies were done to confirm the Ucn3-induced E-cadherin endocytosis (Figure 
S4). Cell dissociation and endocytosis of E-cadherin, upon Ucn3 exposure was prevented by 
pre-treatment with the Src family inhibitor PP2, indicating that Src activation was required for 
the Ucn3-mediated cell-cell contacts disruption (Figure 3C). In SW620 cells, which express 
low level of E-cadherin and perform few AJ, blockade of CRF2 signaling by its specific 
agonist astressin2b (A2b) for 24h was responsible of an increased expression of E-cadherin 
(Figure 3D). Immunofluorescence analysis of E-cadherin distribution in SW620 cells showed 
weak membrane expression and cell-cell contacts with or without Ucn3 (Figure 3E). In 
presence of A2b, SW620 cells formed clusters and E-cadherin was localized at the cell-cell 
contacts. Ucn3 slightly reversed A2b-induced cell clustering. Modulation of adhesive 
proprieties of SW620 cells were also evidenced in aggregation assays, showing that both 
adherent and non adherent cells were able to aggregate in presence of A2b (Figure S5).  
 12 
E-cadherin is associated with catenins at AJ complexes. Disruption of cell-cell 
contacts leads to AJ proteins dissociation and cytoplasmic and/or nuclear localization of 
catenins, which promote cell invasion in CRC [26]. In HT-29 cells treated with Ucn3, p120ctn 
was accumulated in the cytoplasm and the nucleus (Figure 4A). In the nucleus, p120ctn has 
been described to regulate the activity of the transcription factor Kaiso. Ucn3 significantly 
increased p120ctn and Kaiso nuclear expression as observed by immunoblotting after nuclear 
fractionation (Figure 4B). To identify the signaling molecules involved in this nuclear 
shuttling, we tested the effect of Src (PP2) and MEK (U0126) inhibitors. As shown on Figure 
4C, we found that these inhibitors reversed the Ucn3-induced nuclear accumulation of these 
proteins. They also induced an increase of basal nuclear expression of p120ctn and Kaiso, 
probably due to their toxic effect. The nuclear distribution of Kaiso was further analyzed by 
confocal microscopy (Figure 4D). The percentage of nuclei positive for Kaiso increased about 
40% in HT-29 cells treated with Ucn3. Interestingly, in control cells, cells corresponding to 
nuclei positive for Kaiso were observed at the periphery of the cluster, which corresponds to 
cells with less intercellular contacts. Under Ucn3, cells at the centre of the cluster became 
positive for nuclei labeling of kaiso. 
Taken together our data indicate that CRF2 signals through a Src pathway to induce AJ 
disruption by E-cadherin endocytosis. This is followed by p120ctn and Kaiso nuclear 
translocation. Through this route, CRF2 may participate in cell dedifferentiation and 
migration. 
 
CRF2 signaling reorganizes cell-matrix contacts in favor of cell migration and invasion 
 Cancer cell migration is required for metastasis and results from the reorganization of 
cell-cell and cell-matrix contacts. Ucn3-induced cell dissociation was also associated with cell 
shape remodeling as observed by actin cytoskeleton staining with phalloidin-TRITC at the 
basal pole of HT-29 cells (Figure 5A). In untreated cells, actin was distributed at the cell 
periphery and organized as stress fibers spread across the cells. With Ucn3, the actin staining 
was less intense at the cell periphery where contacts are dissociated. There were also fewer 
stress fibers, which appeared shorter and more fragmented. The remodeling of cell shape is 
driven by intra-cellular kinases signaling. In this line, the ERK pathway has also often been 
activated in response to CRF2 activation. In HT-29 CRF2-GFP cells, we showed that ERK 
was phosphorylated on Tyr204 in a short time frame after Ucn3 exposure (Figure 5B). The 
ratio of phosphorylated/total ERK was increased by a 2.5 fold between 5 and 15 min and 
returned to its basal level at 30 and 60 min. PP2, reversed the ERK activation induced by 
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Ucn3 without changing its basal level (low panel). The MEK inhibitor, U0126, induced the 
loss of the phosphorylated forms of ERK under basal conditions and after Ucn3 treatment. 
Cell adhesion remodeling and migration involves the focal adhesion (FA) kinase (FAK). This 
kinase could be phosphorylated on Ser910 by the ERK Ser/Thr kinase. We have thus 
determined the level of FAK phosphorylation in HT-29 CRF2-GFP cells exposed to Ucn3 
(Figure 5C). FAK PSer910 was transiently increased with a maximum at 30 min. This 
phosphorylation was slightly inhibited by PP2 and U0126 under basal conditions and 
abolished under Ucn3 treatment. These data suggest that Ucn3 activates a Src/ERK/FAK 
phosphorylation cascade through the CRF2 receptor. 
 FA structures, which are regulated by FAK, participate in cell-ECM interactions. 
These interactions are mediated by various transmembrane receptors such as integrins, linked 
to cytoskeleton components and scaffold molecules like vinculin [27]. We analyzed the effect 
of Ucn3 on FA through the distribution of vinculin (Figure 5D). Without Ucn3, vinculin was 
expressed in strong patches distributed mainly at the cell periphery. With Ucn3, smaller 
punctuated claws appeared in vinculin staining that were homogeneously distributed all over 
the cell and still not restricted at the periphery, especially at 30 min. The quantification of 
these patches by size revealed that small patches increased while large remain unchanged 
(Figure 5E). This label suggests the formation of nascent focal contacts, which have been 
previously described to participate in cell adhesion and migration [28]. We have performed 
cell adhesion experiments in order to test if the Ucn3-induced vinculin reorganization could 
alter cell attachment to collagen IV (CoIV) and laminin 332 (LM-332) (two major ECM 
proteins of colon’s basal lamina) (Figure 6A). Ucn3 decreases HT-29 cell adhesion on these 
two matrix components at 20 and 60 min of plating. To determine if this effect was associated 
to migration and/or to invasion we tested the impact of Ucn3 on HT-29 cell motility by 
transwell migration and Matrigel invasion assays (Figures 6B and C). Ucn3 treatment 
significantly increased the level of cell migration and invasion compared to control cells. This 
effect was not supported by modification of cell viability (Figure 6D), but could be regulated 
by secretion of matrix metalloproteases (MMPs). We hence examined the expression and the 
activity of MMPs. As shown in Figure 6E, mRNA levels for MMP3 and MMP7 were found 
to be transiently increased by Ucn3. We didn’t observed significant modulation of MMP2 and 
MMP9 transcripts (data not shown). These results were confirmed at protein levels (Figure 
6F). We next examined by a gelatin degradation assay, if HT-29 cells secreted functionally 
active MMPs that have been reported to play a role in carcinoma invasion through 
extracellular matrix degradation. As shown in Figure 6G, MMP enzyme activity was present 
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in unstimulated cell line supernatants, and stimulation with Ucn3 resulted in an increase in 
MMP activity. 
Altogether, these data indicate that CRF2 signaling induced important cell adhesion 
remodeling. At the basal pole, ECM and cell-matrix contacts are remodeled, leading to a 
decreased adhesion on CoIV and LM-332 substratum. These modifications favor cell 
migration and invasion and provide evidence that CRF2 signaling may contribute to invasive 
phenotype of CRC. 
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Discussion 
 
The CRF2/Ucns system is up-regulated in high grade CRC. Our in vitro data highlight the 
functional relevance of this CRF2 over-signaling in the regulation of cell adhesion that 
contribute to epithelial-mesenchymal transition (EMT)-like process with enhance migration 
and invasion.  
CRF receptors and ligands are expressed in many types of cancers and cancer cell lines 
[29,30]. Their inappropriate secretion is sometimes correlated with tumor aggressiveness [31]. 
However no value as tumor marker has been found for CRF receptors in lung and breast 
cancer respectively, whereas in endometrial cancer, CRF1 expression is correlated with less 
aggressive tumors, whereas CRF2 expression is increased in the cytoplasm of advanced stage 
tumor cells [32]. In the colon, we found that CRF2 expression (at transcript and protein 
levels) was increased in CRC according to their grade and/or differentiation status. Likewise 
Ucn2/3 are overproduced in high-grade tumors and there is a balance between Ucn2 
expression and epithelial markers observed in CRC cell lines suggesting that an autocrine 
activation of CRF2 could take part in the progression of CRC cells. 
Thus it is clear that the two CRF receptors exhibit different distributions (cellular and 
subcellular) and hold distinct roles in cancer cells, which could even be counteracting. CRF 
signaling, in particular CRF1, has been described to regulate either tumor initiation and 
progression or tumor inhibition, affecting cell proliferation, apoptosis or tumor angiogenesis 
(for review [15,33]) while CRF2 may play a role in the invasiveness [16,34]. In this work, we 
first described that CRF2 may also contribute to an EMT-induced cell disorganization and 
dedifferentiation that could be associate to metastatic progression. Indeed, in HT-29 cells, we 
found that CRF2 activation induced weakness and disruption of AJ, a process associated to 
the endocytosis of E-cadherin expression and to the nuclear localization of p120ctn and 
Kaiso. Inversely, in SW620 cells, which express low level of E-cadherin, blockade of CRF2 
autocrine activation by A2b induces E-cadherin re-expression and cell clustering.  Src kinase 
activity is increased in many CRC and has been described to trigger cell-cell junction 
disassembly [35] and induce nuclear translocation of p120ctn in tumor cells lacking E-
cadherin [5,36]. An association between Src and CRF1 following short-term treatment with 
Ucn has been initially described in cardiomyocytes and plays an essential role in urocortin-
mediated cardioprotection [23]. We observed that Src is rapidly activated (phosphorylation on 
tyr418) and recruited to CRF2 in response to Ucn3 signaling. Pretreatment with PP2 
abolished Ucn3-induced disruption of cell-cell contacts and p120ctn/Kaiso nuclear 
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translocation suggesting an active role of Src in these effects. P120ctn nuclear translocation 
could relieve Kaiso-mediated repression of several cancer-related genes, such as MMP7 or 
Wnt11 (for review [7]). In addition to its repression activity, Kaiso also contains enhancer 
motifs in which the function of p120ctn binding is unknown [37]. We found that Ucn3 
induced both the regulation of p120ctn/Kaiso nuclear ratio and the transcription of MMP3 and 
MMP7. These results were confirmed at protein levels. Ucn3 also induced a secretion of 
MMP2 and MMP9 in cultured medium measured by zymography. However MMP2 and 
MMP9 mRNA expression was unaffected by Ucn3 under the conditions of our experiments, 
indicating that Ucn3 may also regulate MMP production at the level of posttranslational 
processing. A similar regulation of MMP9 by Ucn has been described in cultured cells from 
human placenta [38]. During cancer progression, these MMP enhance cell migration and 
invasion by degrading ECM components [39] or extracellular fragment of E-cadherin, thus 
disrupting AJ [40].  
Elevated nuclear levels of Kaiso are frequently seen in human cancers including CRC and 
Kaiso-deficient mice show resistance to intestinal cancer [41]. Interestingly, invasive cells at 
the border of the tumor have increased levels of nuclear Kaiso [42]. In HT-29 cells, cells 
positive for nuclear kaiso were principally found at the periphery of the cell cluster. Under 
Ucn3, positive cells for nuclear kaiso reached the center of cell cluster. The nuclear 
localization of kaiso that correlates to reduction of contacts with the cell matrix or 
surrounding cells could represent an indicator of cell adhesion dynamic. Our in vitro assays 
establish conditions that activate colon cancer cell motility through a Src/ERK/FAK pathway, 
thus supporting a role for CRF2 signaling in tumor progression and metastasis. These 
observations would need to be supported by in vivo assays. In CRC, transient ERK activation 
seems to be sufficient to induce FAK phosphorylation on Ser910 and subsequent migration and 
metastasis [43,44]. In HT-29 cells, the CRF2 is also responsible for a transient increase in 
ERK activation that leads to FAK-PSer910. Furthermore, activated Src is required to activate 
ERK, since PP2 also abolished Ucn3-induced phosphorylation of ERK. This signaling could 
modulate the association of FAK with the scaffold protein paxillin [45], which regulates the 
FA turnover and actin cytoskeleton plasticity at the basal pole of the cell. Structurally, we 
found that CRF2 activation leads to a decrease of organized stress fibers in favor of shorter 
and less polarized ones. This cytoskeleton reorganization occurs concomitantly with the 
decrease of cell adhesion on ECM and the formation of small vinculin patches. This is in 
agreement with smaller patches of paxillin and vinculin observed in metastatic-derived cell 
lines (SW620) compared to their primary tumor-derived cell lines (SW480) [28]. Previous 
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studies have demonstrated that the alteration of FA complexes is involved in the 
transmigration of SW480 and HT-29 cells [46]. The CRF2-induced impairment of AJ 
combined to FA complexes remodeling could favor HT-29 cell transmigration. 
 
 Stress participates in the development and aggravation of gastrointestinal disorders 
(for review [47,48]). Indeed CRF2 and its ligands are overexpressed in the colon of 
inflammatory bowel diseases patients while AJ protein expression is altered [49]. We found 
that similar CRF2-dependent cell adhesion alterations occur in tumor cells thus providing a 
new role of stress-related CRF system in CRC. Overall, our data suggest that Ucn3 stimulates 
cell motility and invasiveness of HT-29 cells most probably via induction of FAK 
phosphorylation and actin filament reorganization. Based on these findings we postulate that 
the stress neuropeptide Ucn3 present in the vicinity of tumors (either produced locally by the 
tumor cells themselves or by nearby normal cells or secreted from the innervations of 
surrounding tissues) could promote an EMT-like process and play an important role on colon 
cancer cell metastatic capacity, providing a potential link between stress and tumor 
progression. According to its potential implication in growth, angiogenesis, migration and 
metastasis, via activation of locally expressed ligands, the CRF2 could be clinically exploited 
as a target for new therapeutic approaches. 
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Table 1: Oligonucleotide sequences of primers used for qPCR and RT-PCR.  
GAPDH, glyceraldehydes-3-phosphate dehydrogenase; MMP, matrixmetalloproteinase; PGK, 
phosphoglycerate kinase; HPRT, human phosphoribosyltransferase.  
 qPCR Forward Reverse UPL 
PGK X ctgtggcttctggcatacct cgagtgacagcctcagcata 42 
HPRT X tgaccttgatttattttgcatacc cgagcaagacgttcagtcct 73 
Ucn2 X tgccccacagagtcacagt tgtggcagtgacccaactta 64 
Ucn3 X ggagggaagtccactctcg gggcttggctttgtagaactt 4 
CRF2α X tcctgcgaaatgtcatgtg tgaagatggtggtgatgcag 18 
Cdh1 X tggaggaattcttgctttgc cgctctcctccgaagaaac 84 
Krt20 X tgtcctgcaaattgataatgct agacgtattcctctctcagtctcata 66 
Vim X tggtctaacggtttccccta gacctcggagcgagagtg 56 
MMP3  tgtagaaggcacaatatgg cagtcacttgtctgttgcaca - 
MMP7  atggggaactgctgacatc ccagcgttcatcctcatcga - 
GAPDH  tcctcctgcacagtca caccaccttcttgatgtcatc - 
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Table 2: Patient’s clinicopathological findings.  
 
F
M
Left colon
Right colon
Cases
(n=30) Mean SEM p value Mean SEM p value Mean SEM p value
pN0M0 19 12,0 2,4 1,1 0,5 4,3 0,9
pN1M0 4 28,1 13,8 0,5 0,3 7,8 2,5
pN0M1 3 13,4 5,1 5,0 2,5 11,5 5,7
pN1M1 4 18,0 9,2 4,4 1,5 9,6 4,4
N0 23 14,8 3,2 1,0 0,4 4,9 0,9
N1 7 16,0 5,4 4,7 1,3 10,4 3,2
M0 22 12,2 2,1 1,6 0,6 5,3 1,2
M1 8 23,0 7,9 2,4 1,0 8,7 2,4
Normal 30 1,0 0,4 1,0 0,3 1,0 0,4
Low 19 12,0 2,4 1,1 0,5 4,3 0,9
High 11 20,4 5,9 3,2 1,0 9,5 2,2
WT 12 14,7 3,4 2,6 1,0 7,7 1,9
Mut 17 16,3 4,1 1,2 0,5 4,9 1,2
MSS 24 15,1 3,2 1,2 0,4 5,1 1,0
MSI 5 18,1 4,0 4,5 2,0 10,4 3,6
Age
Sex
Localization
mRNA study
median 75 (16 - 92)
n=12
n=18
n=13
n=17
Lymph nodes
CRF2α Ucn2 Ucn3Characteristic
pTNM 0,5385 0,038 0,1649
0,2054
<0,001 0,1570 <0,001
0,7874 0,005 0,0817
0,260 0,5267
0,1768
Metastasis
K-Ras/B-Raf
MSI
Grade
0,2366 0,019 0,094
0,9823 0,1266
 20 
Figure Legends 
 
Figure 1: CRF2 and ligand expression are increased in high grade and poorly 
differentiated human CRC 
(A) Histograms representing CRF2α, Ucn2 and Ucn3 transcript expression normalized to the 
housekeeping gene PGK (phosphoglycerate kinase) in human normal tissues or CRC (low and 
high grades). (B) Representative CRF2 immunohistochemistry performed on CRC tissues 
from low to high grade. Scale bar, 50 µm. (C) Histograms representing CRF2 protein 
expression quantified from immunohistochemistry. Each sample is represented as dark bars 
+/- SD (left) and the mean value of each group +/- SD (right). High grade is statistically 
different from normal at *, p<0.05.   
 
Figure 2: Characterization of CRF2/Ucns and cell differentiation marker expression in 
CRC cell lines 
(A) Characterization of HT-29 and SW620 cell lines by mRNA expression of Ucn2, Vimentin 
(Vim) and E-cadherin (Cdh1) normalized to the housekeeping gene HPRT (human 
phosphoribosyltransferase). (B) E-cadherin/actin and CRF2/actin protein expression 
quantified by immunoblot in SW620 and HT-29 cell lines. (C) Confocal microscopy analysis 
of CRF2-GFP distribution in Ucn3-treated HT-29 cells. Scale bar, 15 µm. (D) Confocal 
microscopy analysis of CRF2-GFP and E-cadherin distribution in HT-29 cells. Scale bar, 20 
µm. 
 
Figure 3: CRF2 signaling disrupts AJ 
(A) Immunoblot analysis of Src-PTyr418 and Src total expression in HT-29 cells following the 
time course of Ucn3 treatment. (B) Confocal analysis of E-cadherin distribution in HT-29 
cells pretreated with cycloheximide before Ucn3 treatment. Scale bar, 15 µm. (C) Effect of 
PP2 (10 µM, 1 hr) on E-cadherin distribution in HT-29 cells treated or not with Ucn3, 
analyzed by epifluorescence microscopy. Scale bar, 20 µM. (D) Effect of CRF2 antagonist 
(A2b, 8 nM, 24 hrs) on E-cadherin expression in SW620 cells. Quantification was performed 
from immunoblots and normalized to actin. (E) E-cadherin distribution in SW620 cells 
pretreated or not with A2b and further treated or not with Ucn3. Analyzed were performed by 
epifluorescence microscopy. Scale bar, 10 µM. 
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Figure 4: CRF2-mediated dissociation of AJ leads to nuclear shuttling of p120ctn and 
Kaiso 
(A) Confocal analysis of p120ctn location in HT-29 cells pretreated with cycloheximide 
before Ucn3 treatment. Scale bar, 10 µm. (B) Immunoblot analysis of p120ctn and Kaiso 
protein expression in nuclear extracts from HT-29 cells treated or not with Ucn3 (expression 
was normalized to histones). (C) Effects of Src and MEK inhibitors (PP2 and U0126: 10 µM, 
1 hr) on p120ctn and Kaiso protein expression in nuclear extracts from HT-29 treated or not 
with Ucn3. Expression was normalized to histones. (D) Confocal analysis of cellular 
distribution of Kaiso in HT-29 cells. Nuclei were stained with Topro3. Cells negative for 
nuclei labeling of Kaiso were circumscribed by a white dotted line. Scale bar, 60 µm.  
 
Figure 5: CRF2 signaling reorganizes cell-matrix contacts 
(A) Phaloidin-TRITC fluorescence is analyzed by confocal microscopy at the basal pole of 
HT-29 CRF2-GFP cells following Ucn3 treatment. Scale bar, 5 µm. (B) ERK-PTyr204/ERK 
total ratio quantified from immunoblot in HT-29 cells treated with Ucn3 (0 to 60 min) (Upper 
panel). Effects of Src (PP2: 10 µM, 1 hr) or MEK (U0126: 10 µM, 1 hr) inhibitors on Ucn3 
induced ERK-PTyr204 (Lower panel). (C) Ucn3-mediated phosphorylation of FAK- PSer910 in 
HT-29. Quantifications were performed from immunoblots and normalized to actin (upper 
panel). Effects of Src (PP2, 10 µM, 1hr) and ERK (U0126, 10 µM, 1 hr) inhibitors on Ucn3 
induced FAK-PSer910 (Lower panel). (D) Confocal analysis of vinculin distribution at the basal 
pole of HT-29 following Ucn3 treatment. Scale bar, 20 µm. (E) Quantification of the patch 
number by size at 30 min of Ucn3 treatment.  
 
Figure 6: CRF2 signaling alters cell adhesion in favor to cell migration and invasion  
(A) HT-29 were treated or not with Ucn3 (100 nM) 30 min before adhesion and then plated 
on either COIV or LN-332. Cell-ECM adhesion was evaluated at 60 min with the use of a 
Cell Titer Aqueous MTT reagent kit. Values are normalized to the adhesion without Ucn3. 
Data represent the mean +/- SEN of 4 separate experiments. Effect of Ucn3 on HT-29 cells 
transmigration after 72 hrs was determined using a transwell assay (B) and on HT-29 cell 
invasion after 48 hrs by a matrigel assay (C). In both assays cells were visualized by phase 
contrast microscopy and counted. A phase contrast image has been joined. A circle has 
indicated some migrating cells and some invaded cells have been indicated by a white arrow. 
Data (n >3) are given as mean +/- SEM. (D) Effects of Ucn3 on HT-29 cell viability. (E) 
Regulation of MMP3 and MMP7 mRNA expression analyzed by RT-PCR in HT-29 cells 
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treated with Ucn3 100 nM. (F) Immunoblot analysis of MMP3 and MMP7 protein expression 
in HT-29 cells following the time course of Ucn3 treatment. (G) Zymogram of gelatinolytic 
activities in supernatant of HT-29 cells treated or not with Ucn3 (100 nM) during 24 and 48 
hrs. 
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Supplementary figures: 
 
(S1) CRF2 expression is inversely correlated to cell differentiation markers in CRC cell 
lines. Correlated mRNA expression of Ucn2 with Vimentin (Vim), E-cadherin (Cdh1) and 
Keratin 20 (Krt20) in 17 CRC cell lines, normalized to the house keeping gene HPRT (human 
phosphoribosyltransferase). 
 
(S2) Adenylyl cyclase-dependent production of cAMP in HT-29 cells. cAMP production +/- 
SD by HT-29 cells treated with 1µM CRF, Ucn2 or Ucn3 in presence of 1µM of astressin2b 
(A2b) (gray bars)  or not (dark bars). At the concentration of 1µM, CRF, Ucn2 and Ucn3 
induced respectively 0.5, 1.0 and 2.4 pM of cAMP/ 105 cells, which was completely reversed 
by A2b, a selective CRF2 antagonist.  
Method: Cells were treated as described; lyzed in 0.1M HCl, centrifuged (600g 20 min at RT) 
and supernatant were quantified for cAMP using the ELISA kit: CorrelateTM EIA (Assay 
designs) according to the manufacturer’s instructions. All experiments were done in 
triplicates. 
 
(S3) Interaction between SrcPTyr418 and CRF2 receptor.  
The association between Src-PTyr418 and CRF2 has been tested by co-immunoprecipitation 
experiments (A). CRF2 was immunoprecipitated from total lysate of Ucn3-treated HT-29 
cells and levels of Src-PTyr418 and CRF2 were detected by immunoblots. (B) Confocal analysis 
of CRF2-GFP (green) and Src-PTyr418 (red) distribution in HT-29 CRF2-GFP treated with 100 
nM Ucn3 (left). Scale bar, 10 µM. Quantification of CRF2-GFP and Src-PTyr418 co-
localization (right). * are statistics vs t=0 and $ are statistics versus 5 min of Ucn3.  
CRF2/Src-PTyr418 interaction was increased after 5 and 10 min of exposure to Ucn3.  
Furthermore, confocal microscopy analysis indicated a 6-fold increase (at 5 min) in the % of 
CRF2-GFP co-localized with Src-PTyr418 at the basal pole of HT-29 CRF2-GFP cells in 
presence of Ucn3.  
Methods: For immunoprecipitation experiments cells were lysed in RIPA buffer containing 
protease and phosphatase inhibitor cocktails. An equal volume of each condition was 
immunoprecipitated using the PureProteomeTM Protein A and Protein G Magnetic beads kit 
(Millipore) according to manufacturer’s instructions. Mouse and Rabbit Trueblot antibodies 
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used as secondary antibodies in immunoprecipitation experiments were from eBioscience 
(Cliniscience, Montrouge, France). 
 
(S4) Ucn3-induced E-cadherin endocytosis. A) Confocal analysis of E-cadherin endocytosis. 
HECD-1 antibodies directed against the extra-cellular domain of the E-cadherin in HT-29 
CRF2-GFP treated (right) or not (left) with Ucn3 100 nM. Scale bar, 5 µm. B) Westernblot 
analysis of E-cadherin and p120ctn according to a time course of Ucn3 (100 nM). 
Methods: Coverslips were incubated at 4°C with the HECD-1 antibody diluted at 1:100 in 
PBS. After 1h, unspecific binding was removed with three PBS washes and coverslips were 
returned to the initial cell culture condition, with or without Ucn3. As mentioned, cells were 
washed on ice with PBS /NaCl 0.5M /Acetic acid 0.5M /Azide 10mM to remove antibodies 
associated with extracellular cadherins. Coverslips were then treated like 
immunofluorescence. 
 
 (S5) Blockade of CRF2 signaling induces cell aggregation. Effect of A2b (1 µM, 
Overnight) on cell clustering in culture conditions (left) and on cell aggregation assays (right).  
Method: HT-29 cells were harvested from monolayer cultures as previously described by 
(Nakagawa and Takeichi, 1995).  To preserve the integrity of E-cadherins at the cell surface, 
cells were resuspended at a density of 106 cells/ ml of TBS containing 10 mM HEPES /1 mM 
CaCl2. Aggregation assays were performed in a 24-well plate saturated with BSA and 
extensively washed. The cell suspensions were incubated at 37°C in a gyratory shaker at 75 
rpm for 30 min. Cell aggregation was observed with an inverted microscope (Zeiss Axiovert 
135) under phase contrast and photographs were taken with a CCD camera (Hitachi Denshi, 
Ltd.). Nakagawa, S., and Takeichi, M. (1995). Neural crest cell-cell adhesion controlled by 
sequential and subpopulation-specific expression of novel cadherins. Development 121, 1321-
32. 
 
 
 28 
  
 
 
Figure 1
A
B
C
Normal 
tissue Low to High grade tumors
CR
F2
 im
mu
no
sta
inin
g
(fo
ldi
ncr
ea
se
ove
rn
orm
al )) ))
0
1
2
3
4
5
Normal Low grade High grade
m = 1.0 (+/- 0.1)
n =  9, (22% > 1) 
m = 1.3 (+/- 0.2)
n = 24, (33% > 1) 
m = 1.9 (+/- 0.3)
n =  18, (72% > 1) 
0
0,5
1
1,5
2
2,5
Norm
al
Low
grad
e
High
grad
e
CR
F2
 ex
pre
ssi
on
(fo
ldi
ncr
ea
se
ove
rn
orm
al) *
CR
F2
α
mR
NA
exp
res
sio
n
(fo
ldi
ncr
ea
se
ove
rn
orm
al)
0
10
20
30
Norm
al
Low
grad
e
High
grad
e
CRF2α
Uc
n2
 m
RN
Ae
xpr
ess
ion
(fo
ldi
ncr
ea
se
ove
rn
orm
al)
0
1
2
3
4
5 Ucn2
Norm
al
Low
grad
e
High
grad
e Uc
n3
 m
RN
Ae
xpr
ess
ion
(fo
ldi
ncr
ea
se
ove
rn
orm
al)
0
5
10
15 Ucn3
Norm
al
Low
grad
e
High
grad
e
**
***
**
**
0 min 15 min
Ucn3 100 nM
Figure 2
A
B C
0
1
2
3
4
5
6
7
8
9
10
HT-29 SW620
Uc
n2
 m
RN
Ae
xpr
ess
ion
0
0,2
0,4
0,6
0,8
1
1,2
HT-29 SW620
Vim
mR
NA
exp
res
sio
n  
    
    
HT-29 SW620
0
0,2
0,4
0,6
0,8
1
1,2
Cd
h1
 m
RN
Ae
xpr
ess
ion
    
    
  
Ucn2 Vim Cdh1
CRF2 E-cadherin
SW
620 HT-
29
Actin
SW
620 HT-
29
De
nsi
tom
etr
icu
nit
(pr
ote
ine
xpr
ess
ion
/ac
tin)
 
0
0,2
0,4
0,6
0,8
1
1,2
HT-29
SW 620
CRF2 E-cadherin
Control
Ucn3
( 1hr, 100 nM)
Ucn3
(5 hrs, 100 nM)
Wi
tho
ut
A2
b
Wi
th
A2
b
Figure 3
* *
E-cadherin
Actin
E-c
ad
he
rin
/Ac
tin
exp
res
sio
n
- A2b +A2b0
0,5
1
1,5
2
2,5
3
1 hr
Uc
n3
 10
0 
Uc
n3
 10
0 
Uc
n3
 10
0 
Uc
n3
 10
0 n
MnM nMnM
Co
ntr
ol
Co
ntr
ol
Co
ntr
ol
Co
ntr
ol
0 hr
A
Src
Src-P
0 5’ 10’ 15’ 30’ 60’Ucn3 100 nM 0 5’ 10’ 15’
IP CRF2
Src-P
Ucn3 100 nM
C
B
D
FE
Co
ntr
ol
Co
ntr
ol
Co
ntr
ol
Co
ntr
ol
PP
2
PP
2
PP
2
PP
2
0 hr 1 hr 5 hrs
1 hr 5 hrs0 hr
Figure 4
A
CB
D
p1
20
ctn
p1
20
ctn
p1
20
ctn
p1
20
ctn
15’0’ 30’ 60’
Ka
iso
/his
ton
e e
xpr
ess
ion
(fo
ldi
ncr
ea
se
ove
r0
) Ucn3 100 nM
Histones
Kaiso
0 1hr 2hrs
*
5hrs
*
0
1
2
3
4
P1
20
ctn
/his
ton
e e
xpr
ess
ion
(fo
ldi
ncr
ea
se
ove
r0
) Ucn3 100 nM
Histones
p120ctn
0
1
2
3
4
0 1hr 2hrs
*
5hrs
**
Ucn3 100 nM
Ucn3 5hrs
Ucn3 5hrs
Ctr PP2
Ucn3 0hr
Kaiso
p120ctnUcn3 0hr
0 hr 5hrs
Ucn3 100 nM
Figure 5
A
D
B
15’ 30’ 60’0’
Ucn3 100 nM
5’
30’15’
0’
FAK-P
Actin
Ucn3 (10’ )PP2U0126
- - - +      +     +- +      - - +     -- - +     - - +
0
1
2
3
4
FA
K-P
/Ac
tin
pro
tein
rat
io
(fo
ldi
ncr
ea
se
vs 
0)
*
*
*
Ucn3 100 nM
FAK-P
Actin
0 5’ 10’ 15’ 30’ 60’
C 
0
10
20
30
40
50
60
Total Small Medium Large
Ctr
30' Ucn3
***
***
*
% 
are
a o
fvi
ncu
lin
lab
elli
ng
ERK-P
ERK
Ucn3 (10’ )PP2U0126
- - - +     +    +- +    - - +     -- - +    - - +
0
1
2
3
ER
K-P
/ER
K p
rot
ein
rat
io
(fo
ldi
ncr
ea
se
vs 
 0) ** *****
Ucn3 100 nM
ERK-P
ERK
0 5’ 10’ 15’ 30’ 60’
D E
BA
MMP7
MMP3
0 hr 5 hrs 24 hrs
MM
P/G
AP
DH
 m
RN
Ar
atio
(Fo
ldi
ncr
ea
se
ove
rC
tr)
GAPDH
Ucn3 100 nM
MMP3 MMP7
0
1
2
3
4
*
**
D E
C
Figure 6
**
0
1
2
3
4
Ucn3Ctr
Ce
llin
vas
ion
 
(Fo
ldi
ncr
ea
se
ove
r
Ctr
)
Ce
lltr
an
sm
igr
atio
n
(Fo
ldi
ncr
ea
se
ove
r
Ctr
)
0
1
2
***
Ucn3Ctr
Ce
lla
dh
esi
on
(in
de
x v
sC
tr)
0
0,2
0,4
0,6
0,8
1
1,2
COIV LN-332
Ctr Ucn3
******
Ce
llv
iab
ility
(in
de
x v
s 0
 hr
)
0
0,5
1
1,5
2
2,5
3
0 hr 48 hrs 72 hrs
5’
0’
CFR2-GFP/Src-P
30’
15’
CR
F2
-G
FP
/Sr
c-P
Ty
r41
8 c
olo
cal
iza
tion
(fo
ldi
ncr
ea
se
ove
rC
tr)
Ucn3 100 nM
***
**
**# #
0
1
2
3
4
5
0 5’ 15’ 30’
Supplementary Figure S2
0
1
2
3
CRF Ucn2 Ucn3
cA
MP
pro
du
ctio
n
10
5 c
ells
in 3
0 m
in
- + - + - +A2b
Supplementary Figure S1
CaCl2 (2 nM)
CaCl2 (2 nM)Ucn3 (100 nM)EDTA (5 nM)
Without
Astressin
2b
With
Astressin
2b
On adherent cells In cell aggregation assay
CaCl2 (2 nM)
Supplementary Figure S4
Supplementary Figure S3
Ucn3
100nM
Ucn3
0nM
HECD1A
60’
15’
60’
15’
B
Actin
E-cadherin
0 1 2 5 24
p120ctn
Ucn3 100 nM (hrs)
